Join industry leaders, investors, and seasoned regulatory counsel for an exclusive event focused on thriving during times of change in the life sciences sector. Through dynamic panel discussions, we’ll explore the latest trends in regulation, financing, market dynamics, and federal health policy, all with a focus on how companies can continue to realize the transformative impact of new therapies and technologies. Don’t miss this opportunity to connect, learn, and chart a new course for long-term business success.
RSVP here.
AGENDA
Registration | 1:00 p.m.
Program | 1:30 p.m.
Reception 4:30 p.m.
Who may be interested in attending: Executives, Directors, Investors, and In-House Counsel
FEATURED PANELS
Regulatory Realities – Proactive Strategies in a Shifting Landscape
Explore how companies are developing new strategies to respond to the latest developments at HHS, FDA, and CMS, including major shifts in FDA leadership, staffing, and policy priorities, potential impacts on regulatory timelines and new product approvals, and new proposals related to drug pricing and reimbursement. Hear from industry insiders on how to engage effectively with regulators and adapt to new expectations in an era of uncertainty.
SPEAKERS
- Anthony Davies, Ph.D., Founder & CEO, Dark Horse Consulting
- Hae-Won Min Liao, Vice President, U.S. Legal Business Partner, Gilead Sciences
- Emily Marden, Senior Counsel, Sidley
- Catherine Starks, Partner, Sidley
Additional panelists to be announced
Financing the Future – Paths to Growth and Liquidity
Discover how investment opportunities are evolving, with a focus on financing and liquidity options including debt, royalty financing, mergers, and other strategic transactions. Leading advisors and investors will share their experience, including how shifting geopolitical and regulatory factors are shaping deals, and what it takes to secure funding and achieve liquidity in today’s market.
SPEAKERS
- Ryuk Byun, Managing Director, Morgan Stanley
- Hutch Corbett, Managing Partner, Armentum Partners
- Carlton Fleming, Partner, Sidley
- Frank Rahmani, Partner, Sidley
Additional panelists to be announced
The GLP-1 Effect – Disruption, Demand, and What’s Next for Biotech
Using GLP-1 as a case study, dive into the latest trends in product development, pricing and reimbursement, market dynamics, and federal health policy. This panel will examine issues that have arisen for the paradigm-shifting GLP-1/GIP/Gcg product category, to reveal for the future of innovation across the entire life sciences industry.
SPEAKERS
- Scott Akamine, Chief Legal Officer, Kailera Therapeutics
- Michael Hulka, Senior Vice President and Deputy General Counsel, Eli Lilly and Company
- Torrey Cope, Partner, Sidley
Additional panelists to be announced
CLE credit for this program is pending.
For more information, contact sfevents@sidley.com.